Epirubicin

Back to search

Molecule Structure

Scientific Name

Epirubicin

Description of the Drug

Epirubicin is an anthracycline topoisomerase II inhibitor used as an adjuvant to treating axillary node metastases in patients who have undergone surgical resection of primary breast cancer.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00445

Brand Name(s)

Not Available

Company Owner(s)

Cipla Ltd, Fresenius Kabi Usa Llc, Mylan Laboratories Ltd, Hospira Inc, Actavis Totowa Llc, Ebewe Pharma Ges Mbh Nfg Kg, Hisun Pharmaceutical (Hangzhou) Co Ltd, Zennova Pharmaceuticals Chengdu Co Ltd, Impax Laboratories Inc, Hikma Pharmaceuticals Usa Inc

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
DNA NUCLEIC-ACID INHIBITOR CHEMBL2311221

Unichem Links

SureChEMBL SCHEMBL8582
PharmGKB PA449476
Human Metabolome Database HMDB0014588
DrugBank DB00445
PubChem: Thomson Pharma 14812446 14837077
PubChem 41867
NMRShiftDB 60022164
LINCS LSM-2078
Nikkaji J81.933F
BindingDB 43839
EPA CompTox Dashboard DTXSID0022987
DrugCentral 1030
Metabolights MTBLC47898
rxnorm ELLENCE EPIRUBICIN HYDROCHLORIDE EPIRUBICIN
KEGG Ligand C11230
ChEBI 47898
ZINC ZINC000003938704